RyR2 inhibitor ent-verticilide is rapidly cleared by CYP3A-driven liver metabolism with low oral exposure in rats
- ent-Verticilide, a synthetic macrocyclic depsipeptide that inhibits ryanodine receptor 2 and is being explored for cardiac arrhythmias, was profiled for metabolism and pharmacokinetics.
- In liver S9 fractions from mouse, rat, dog and human, the compound was depleted quickly in an NADPH-dependent manner; CYP3A was the main contributing enzyme subfamily, and eight putative metabolites formed mainly by hydroxylation, oxidation and desaturation, similar across human and rat.
- In rats, clearance was high, distribution was extensive and oral bioavailability was low, supporting extensive hepatic oxidative metabolism and giving a first DMPK framework for preclinical work.
💡 Points Based on the abstract
High clearance plus low oral exposure is a tough profile for a chronic antiarrhythmic, and S9 depletion alone won't tell you how much is first-pass versus other routes. I'd want unbound plasma and cardiac tissue levels set against RyR2 inhibition potency before blaming metabolism. If CYP3A soft spots are confirmed, blocking them is the obvious step, but the CYP3A drug-interaction burden then needs watching.
Characterizing the Metabolic Fate and Pharmacokinetics of the RyR2 Inhibitor ent-Verticilide ↗